Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Third Rock Ventures, founded in 2007 and based in Boston, has raised $3.8 billion and manages a portfolio of 72 companies. The firm employs 95 professionals, including 26 partners, with expertise in pharmaceutical development and clinical science. They have achieved a return of $3.58 for every dollar invested.
This firm invests in Series A and B stages, providing initial checks between $30 million and $100 million. Their primary focus is on life science companies in biotech, diagnostics, medical devices, therapeutics, and digital health, particularly those addressing ultra-orphan and rare genetic disorders, cancer, cardiovascular disease, and neuropsychiatry.
Notable companies in their portfolio include Maze Therapeutics, Septerna, Blueprint Medicines, Foundation Medicine, Sage Therapeutics, and Editas Medicine, with 19 IPOs and 23 acquisitions. Recent investments include Syremis Therapeutics with a $165 million Series A in December 2025.
Submit your pitch through their form at https://www.thirdrockventures.com/.
As of December 2025: Third Rock Ventures made a notable investment of $165 million in Syremis Therapeutics, continuing their active engagement in the life sciences sector.
Third Rock Ventures focuses on building transformational life science companies at the intersection of science, strategy, business, and medicine, primarily in biotech and digital health.
The firm has invested in 72 companies, achieving 19 IPOs and 23 acquisitions, demonstrating a strong track record in the life sciences sector.
They offer hands-on operational support across drug discovery, clinical strategy, business operations, and talent acquisition, leveraging deep scientific expertise from their team.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.